ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Cancer|Cervical Cancer|Triple Negative Breast Cancer
Interventions: DRUG: ASTX660|DRUG: Pembrolizumab
Sponsor: Institute of Cancer Research, United Kingdom
Collaborators: Astex Pharmaceuticals, Inc.|Merck Sharp & Dohme LLC|Cancer Research UK